Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aortic Root Infusion of Sufentanil for Ischemia-Reperfusion Injury in CABG
IRCT2017080619470N62Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sufentanil in coronary arteriosclerosis and myocardial ischemia-reperfusion injury, sponsored by Shiraz University of Medical Sciences. Started Dec 2017; status: completed.
02
Drugs
sufentanil
03
Conditions
coronary arteriosclerosismyocardial ischemia-reperfusion injury
Beyond the preview
Go deeper on IRCT2017080619470N62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017080619470N62.